Correlation Between Protagonist Therapeutics and Rhythm Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Protagonist Therapeutics and Rhythm Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protagonist Therapeutics and Rhythm Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protagonist Therapeutics and Rhythm Pharmaceuticals, you can compare the effects of market volatilities on Protagonist Therapeutics and Rhythm Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protagonist Therapeutics with a short position of Rhythm Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protagonist Therapeutics and Rhythm Pharmaceuticals.

Diversification Opportunities for Protagonist Therapeutics and Rhythm Pharmaceuticals

0.52
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Protagonist and Rhythm is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding Protagonist Therapeutics and Rhythm Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rhythm Pharmaceuticals and Protagonist Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protagonist Therapeutics are associated (or correlated) with Rhythm Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rhythm Pharmaceuticals has no effect on the direction of Protagonist Therapeutics i.e., Protagonist Therapeutics and Rhythm Pharmaceuticals go up and down completely randomly.

Pair Corralation between Protagonist Therapeutics and Rhythm Pharmaceuticals

Given the investment horizon of 90 days Protagonist Therapeutics is expected to under-perform the Rhythm Pharmaceuticals. In addition to that, Protagonist Therapeutics is 1.03 times more volatile than Rhythm Pharmaceuticals. It trades about -0.12 of its total potential returns per unit of risk. Rhythm Pharmaceuticals is currently generating about -0.09 per unit of volatility. If you would invest  6,204  in Rhythm Pharmaceuticals on November 29, 2024 and sell it today you would lose (872.00) from holding Rhythm Pharmaceuticals or give up 14.06% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Protagonist Therapeutics  vs.  Rhythm Pharmaceuticals

 Performance 
       Timeline  
Protagonist Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Protagonist Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Rhythm Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Rhythm Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Protagonist Therapeutics and Rhythm Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Protagonist Therapeutics and Rhythm Pharmaceuticals

The main advantage of trading using opposite Protagonist Therapeutics and Rhythm Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protagonist Therapeutics position performs unexpectedly, Rhythm Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rhythm Pharmaceuticals will offset losses from the drop in Rhythm Pharmaceuticals' long position.
The idea behind Protagonist Therapeutics and Rhythm Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stocks Directory
Find actively traded stocks across global markets
CEOs Directory
Screen CEOs from public companies around the world